Ian D. Pavord
University of Oxford
667 Papers
5.3K Citations
Ian D. Pavord is an academic researcher from University of Oxford. The author has contributed to research in topics: Asthma & Medicine. The author has an hindex of 108, co-authored 575 publications. Previous affiliations of Ian D. Pavord include John Radcliffe Hospital & University of Warwick.
Chat about Author
Papers
The current and future role of biomarkers in type 2 cytokine-mediated asthma management.
TL;DR: Blood eosinophil count and serum periostin appear to be a biomarker for responsiveness to inhaled corticosteroid therapy and may help identify patients as suitable candidates for anti‐IL‐13 treatment.
Identifying Bacterial Airways Infection in Stable Severe Asthma Using Oxford Nanopore Sequencing Technologies
M Jabeen,Nicholas D Sanderson,Dona Foster,Derrick W. Crook,Jennifer L Cane,Catherine Borg,Clare Connolly,Samantha Thulborn,Ian D. Pavord,Paul Klenerman,Teresa L Street,Timothy S. C. Hinks +11 more
TL;DR: Haemophilus influenzae was a dominant bacterium in the airways in people with severe asthma and was identified reliably using metagenomic sequencing using an optimized method for Illumina MiSeq and Oxford Nanopore.
Asthma in pregnancy: An update.
TL;DR: Asthma is the most frequent comorbid chronic illness in pregnancy and Convincing evidence shows that uncontrolled asthma magnifies the effects of pregnancy-related illnesses.
Cough frequency in health and disease
TL;DR: These questions were set out to address in healthy adult volunteers and adult volunteers with respiratory disease and the performance of the semi-automated computerised Leicester Cough Monitor over 24 h and across the range of expected cough frequency in larger populations.
Optimal Asthma Control: Time for a New Target
Richard Beasley,Richard Beasley,Irene Braithwaite,Alex Semprini,Ciléin Kearns,Mark Weatherall,Mark Weatherall,Ian D. Pavord +7 more
TL;DR: In adults without good asthma control, 'well-controlled' asthma can only be achieved in around 70% of patients across the strata of severity, and only if there is a progressive increase in ICS/LABA therapy to a maintenance ICS dose which causes the same magnitude of systemic side effects as oral prednisone at a 5mg daily dose.